Some structural determinants of the antiproliferative effect of heparin-like molecules on human airway smooth muscle

British Journal of Pharmacology

Volumn 146, Issue 3, 2005, Pages 370-377

  Kanabar, Varsha ^a   Hirst, Stuart J ^a   O'Connor, Brian J ^a   Page, Clive P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Airway; Glycosaminoglycan; Heparin; Proliferation; Remodelling

Indexed keywords

ANTICOAGULANT AGENT; CHONDROITIN 4 SULFATE; DERMATAN SULFATE; DESULFATED DEXTRAN; DEXTRAN SULFATE; FUCOIDIN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; HEPARIN DERIVATIVE; HYALURONIC ACID; LOW MOLECULAR WEIGHT HEPARIN; N DESULFATED HEPARIN; O DESULFATED HEPARIN; POLYGLUTAMIC ACID; SIGMA HEPARIN; UNCLASSIFIED DRUG;

AGED; AIRWAY; ANTICOAGULATION; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOLECULAR WEIGHT; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; SULFATION;

ADULT; AGED; BRONCHI; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HEPARITIN SULFATE; HUMANS; MALE; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; SULFATES;

EID: 27144531365     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706333     Document Type: Article

References (41)

1. BRIGHTLING, C.E., BRADDING, P., SYMON, F.A., HOLGATE, S.T., WARDLAW, A.J. & PAVORD, I.D. (2002). Mast-cell infiltration of airway smooth muscle in asthma. N. Engl. J. Med., 346, 1699-1705.
2. 2 inhibit proliferation of asthmatic and non-asthmatic airway smooth muscle cells in culture. Am. J. Respir. Crit. Care Med., 158, A503 (Abstract).
3. CASTELLOT, J.J., BEELER, D.L., ROSENBERG, R.D. & KARNOVSKY, M.J. (1984). Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. J. Cell Physiol., 120, 315-320.
4. CASTELLOT, J.J., CHOAY, J., LORMEAU, J.C., PETITOU, M., SACHE, E. & KARNOVSKY, M.J. (1986). Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. II. Evidence for a pentasaccharide sequence that contains a 3-O-sulfate group. J. Cell Biol., 102, 1979-1984.
5. DELMOLINO, L.M., STEARNS, N.A. & CASTELLOT, J.J. (2001). COP-1, a member of the CCN family, is a heparin-induced growth arrest specific gene in vascular smooth muscle cells. J. Cell Physiol., 188, 45-55.
6. EBINA, M., TAKAHASHI, T., CHIBA, T. & MOTOMIYA, M. (1993). Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma. A 3-D morphometric study. Am. Rev. Respir. Dis., 148, 720-726.
7. FRYER, A., HUANG, Y.C., RAO, G., JACOBY, D., MANCILLA, E., WHORTON, R., PIANTADOSI, C.A., KENNEDY, T. & HOIDAL, J. (1997). Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J. Pharmacol. Exp. Ther., 282, 208-219.
8. GARG, H.G., CINDHUCHAO, N., QUINN, D.A., HALES, C.A., THANAWIROON, C., CAPILA, I. & LINHARDT, R.J. (2002). Heparin oligosaccharide sequence and size essential for inhibition of pulmonary artery smooth muscle cell proliferation. Carbohydr. Res., 337, 2359-2364.
9. GARG, H.G., THOMPSON, B.T. & HALES, C.A. (2000). Structural determinants of antiproliferative activity of heparin on pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol., 279, L779-L789.
10. GRAINGER, D.J., WITCHELL, C.M., WATSON, J.V., METCALFE, J.C. & WEISSBERG, P.L. (1993). Heparin decreases the rate of proliferation of rat vascular smooth muscle cells by releasing transforming growth factor beta-like activity from serum. Cardiovasc. Res., 27, 2238-2247.
11. GREEN, W.F., KONNARIS, K. & WOOLCOCK, A.J. (1993). Effect of salbutamol, fenoterol, and sodium cromoglycate on the release of heparin from sensitized human lung fragments challenged with Dermatophagoides pteronyssinus allergen. Am. J. Respir. Cell Mol. Biol., 8, 518-521.
12. GUYTON, J.R., ROSENBERG, R.D., CLOWES, A.W. & KARNOVSKY, M.J. (1980). Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Circ. Res., 46, 625-634.
13. HALAYKO, A.J., RECTOR, E. & STEPHENS, N.L. (1997). Characterisation of molecular determinants of smooth muscle cell heterogeneity. Can. J. Physiol. Pharmacol., 75, 917-929.
14. HEARD, B.E. & HOSSAIN, S. (1973). Hyperplasia of bronchial muscle in asthma. J. Pathol., 110, 319-331.
15. HIRST, S.J., BARNES, P.J. & TWORT, C.H. (1992). Quantifying proliferation of cultured human and rabbit airway smooth muscle cells in response to serum and platelet-derived growth factor. Am. J. Respir. Cell Mol. Biol., 7, 574-581.
16. HIRST, S.J., TWORT, C.H. & LEE, T.L. (2000). Differential effects of extracellular matrix proteins on human airway smooth muscle cell proliferation and phenotype. Am. J. Respir. Cell Mol. Biol., 23, 335-344.
17. HOOVER, R.L., ROSENBERG, R., HAERING, W. & KARNOVSKY, M.J. (1980). Inhibition of rat arterial smooth muscle cell proliferation by heparin II. In vitro studies. Circ. Res., 47, 578-583.
18. JAMES, A.L., PARE, P.D. & HOGG, J.C. (1989). The mechanics of airway narrowing in asthma. Am. Rev. Respir. Dis., 139, 242-246.
19. JAQUES, L.B., KAVANAGH, L. & LAVALLEE, A. (1967). A comparison of biological activities and chemical analyses for various heparin preparations. Arzneimittel-Forschung, 17, 774-778.
20. 2 inhibit DNA synthesis in human airway smooth muscle cells in culture. Am. J. Physiol. Lung Cell Mol. Physiol., 269, L514-L519.
21. JOSEPH, P.A., GARG, H.G., THOMPSON, B.T., LIU, X. & HALES, C.A. (1997). Influence of molecular weight, protein core and charge of native heparin fractions on pulmonary artery smooth muscle cell proliferation. Biochem. Biophys. Res. Commun., 241, 18-23.
22. KARNOVSKY, M.J. & EDELMAN, E.R. (1994). Heparin/heparan sulphate regulation of vascular smooth muscle behaviour. In: Airways and Vascular Remodelling in Asthma and Cardiovascular Disease: Implications for Therapeutic Intervention, ed. Page, C.P. & Black, J.L. pp. 45-70. New York: Academic Press.
23. KILFEATHER, S.A., TAGOE, S., PEREZ, A.C., OKONA-MENSA, K., MATIN, R. & PAGE, C.P. (1995). Inhibition of serum-induced proliferation of bovine tracheal smooth muscle cells in culture by heparin and related glycosaminoglycans. Br. J. Pharmacol., 114, 1442-1446.
24. LAKE, A.C. & CASTELLOT, J.J. (2003). CCN5 modulates the antiproliferative effect of heparin and regulates cell motility in vascular smooth muscle. Cell Commun. Signal., 1, 5-18.
25. LAMBERT, R.K., WIGGS, B.R., KUWANO, K., HOGG, J.C. & PARE, P.D. (1993). Functional significance of increased airway smooth muscle in asthma and COPD. J. Appl. Physiol., 74, 2771-2781.
26. LEVER, R. & PAGE, C.P. (2002). Novel drug development opportunities for heparin. Nat. Rev. Drug Discov., 1, 140-148.
27. LONGAS, M.O., GARG, H.G., TRINKLE-PEREIRA, J.M. & HALES, C.A. (2003). Heparin antiproliferative activity on bovine pulmonary artery smooth muscle cells requires both N-acetylation and N-sulfonation. Carbohydr. Res., 338, 251-256.
28. 2+ influx by unfractionated heparin in non-excitable intact cells via multiple mechanisms. Biochem. Pharmacol., 69, 929-940.
29. PAGE, C.P. (1991). One explanation of the asthma paradox: inhibition of natural antiinflammatory mechanism by beta 2-agonists. Lancet, 337, 717-720.
30. PAGE, S., AMMIT, A.J., BLACK, J.L. & ARMOUR, C.L. (2001). Human mast cell and airway smooth muscle cell interactions: implications for asthma. Am. J. Physiol. Lung Cell Mol. Physiol., 281, L1313-L1323.
31. RABENSTEIN, D.L. (2002). Heparin and heparan sulfate: structure and function. Nat. Prod. Rep., 19, 312-331.
32. ROBINSON, D.S. (2004). The role of the mast cell in asthma: induction of airway hyperresponsiveness by interaction with smooth muscle? J. Allergy Clin. Immunol., 114, 58-65.
33. SAN ANTONIO, J.D., LANDER, A.D., WRIGHT, T.C. & KARNOVSKY, M.J. (1992). Heparin inhibits the attachment and growth of Balb/c-3T3 fibroblasts on collagen substrata. J. Cell Physiol., 150, 8-16.
34. SEEDS, E.A., HORNE, A.P., TYRRELL, D.J. & PAGE, C.P. (1995). The effect of inhaled heparin and related glycosaminoglycans on allergen-induced eosinophil infiltration in guinea-pigs. Pulm. Pharmacol., 8, 97-105.
35. SHIELS, I.A., TAYLOR, S.M. & FAIRLIE, D.P. (2000). Cell phenotype as a target of drug therapy in chronic inflammatory diseases. Med. Hypotheses. 54, 193-197.
36. TIOZZO, R., CINGI, M.R., REGGIANI, D., ANDREOLI, T., CALANDRA, S., MILANI, M.R., PIANI, S., MARCHI, E. & BARBANTI, M. (1993). Effect of the desulfation of heparin on its anticoagulant and antiproliferative activity. Thromb. Res., 70, 99-106.
37. TIOZZO, R., REGGIANI, D., CINGI, M.R., BIANCHINI, P., OSIMA, B. & CALANDRA, S. (1991). Effect of heparin derived fractions on the proliferation and protein synthesis of cells in culture. Thromb. Res., 62, 177-188.
38. TYRRELL, D.J., HORNE, A.P., HOLME, K.R., PREUSS, J.M. & PAGE, C.P. (1999). Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv. Pharm., 46, 151-208.
39. VARMA, R. & VARMA, R.S. (1983). Chemistry and metabolism of glycosaminoglycans and proteoglycans. In: Mucopolysaccharides. Glycosaminoglycans of Body Fluids in Health and Disease, pp. 3-48. Berlin: Walter de Gruyter.
40. WINDHOLZ, M., BUDAVERI, S., STROUNTSOS, L. & FERTIG, M. (1976). The Merck Index. 9th edn. pp. 387, New Jersey: Merck Rahway.
41. WRIGHT, T.C.J., CASTELLOT, J.J.J., PETITOU, M., LORMEAU, J.C., CHOAY, J. & KARNOVSKY, M.J. (1989). Structural determinants of heparin's growth inhibitory activity. Interdependence of oligosaccharide size and charge. J. Biol. Chem., 264, 1534-1542.